Natalia Tijaro Ovalle

Natalia Tijaro Ovalle

Auto-generated profile, based on publicly available information

Natalia Tijaro Ovalle

Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, United States

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
3 January 2020 in Science Immunology
Verified
Journal Article
Closed access
PDF file
LSLaura Strauss
Laura Strauss
MMMohamed A. A. Mahmoud
Mohamed A. A. Mahmoud
JWJessica D. Weaver
Jessica D. Weaver
NTNatalia M. Tijaro-Ovalle
Natalia M. Tijaro-Ovalle
ACAnthos Christofides
Anthos Christofides
VBVassiliki A. Boussiotis
Vassiliki A. Boussiotis
PD-1, a T cell checkpoint receptor and target of cancer immunotherapy, is also expressed on myeloid cells. The role of myeloid-specific versus T cell–specific PD-1 ablation on antitumor immunity has remained unclear because most studies have used either PD-1–blocking antibodies or complete PD-1 KO mice. We generated a conditional allele, which allowed myeloid-specific (PD-1f/fLysMcre) or T cell–specific (PD-1f/fCD4cre) targeting of Pdcd1 gene. Compared with T cell–specific PD-1 ablation, myeloid cell–specific PD-1 ablation more effectively decreased tumor growth. We found that granulocyte/macrophage progenitors (GMPs), which accumulate during cancer-driven emergency myelopoiesis and give rise to myeloid-derived suppressor cells (MDSCs), express PD-1. In tumor-bearing PD-1f/fLysMcre but not PD-1f/fCD4cre mice, accumulation of GMP and MDSC was prevented, whereas systemic output of effector myeloid cells was increased. Myeloid cell–specific PD-1 ablation induced an increase of T effector memory cells with improved functionality and mediated antitumor protection despite preserved PD-1 expression in T cells. In PD-1–deficient myeloid progenitors, growth factors driving emergency myelopoiesis induced increased metabolic intermediates of glycolysis, pentose phosphate pathway, and TCA cycle but, most prominently, elevated cholesterol. Because cholesterol is required for differentiation of inflammatory macrophages and DC and promotes antigen-presenting function, our findings indicate that metabolic reprogramming of emergency myelopoiesis and differentiation of effector myeloid cells might be a key mechanism of antitumor immunity mediated by PD-1 blockade.

24 October 2023 in Journal of Cancer Education
Verified
Journal Article
Closed access
PDF file
JGJuan Guio
Juan Guio
AMAndrés Melo
Andrés Melo
MSMateo Mejía Saldarriaga
Mateo Mejía Saldarriaga
CFCynthia Fuentes
Cynthia Fuentes
NTNatalia Tíjaro-Ovalle
Natalia Tíjaro-Ovalle
MRMartha Romero
Martha Romero

15 October 2026 in Blood Advances
Verified
Journal Article
Open access
BFBenjamin F. Frost
Benjamin F. Frost
IVIoannis Kalogirou Valtis
Ioannis Kalogirou Valtis
YFYael Flamand
Yael Flamand
EBEmilie W. Baxter
Emilie W. Baxter
SSShai Shimony
Shai Shimony
ECEvan C. Chen
Evan C. Chen
Although adults with Philadelphia chromosome-positive (Ph+) B-cell acute lymphoblastic leukemia (B-ALL) may achieve a measurable residual disease-negative (MRD-) complete response (CR) after frontline treatment and blinatumomab (blina) consolidation, survival outcomes are heterogeneous, and known prognostic factors are limited. We conducted a retrospective, multicenter study of 81 adults with Ph+ B-ALL in MRD- (<10-4) CR1 after blina consolidation and stratified them by pre-blina MRD status as determined by multiparametric flow cytometry (flow). Patients who were pre-blina flow MRD- (n = 56) and flow MRD+ (n = 25) had similar baseline characteristics. With a median follow-up of 31.0 months, pre-blina flow MRD- patients had superior disease-free (DFS) and overall survival (OS) on univariate (p = 0.049 and p = 0.045, respectively) and multivariable analyses (HR 0.27, 95% CI 0.08-0.87 and HR 0.17, 95% CI 0.03-0.90, respectively) relative to pre-blina flow MRD+ patients. Inferior DFS was seen with the IKZF1-plus genotype (HR 3.51, 95% CI 1.08-11.44) and extramedullary disease at diagnosis (HR 3.90, 95% CI 1.19-12.73). In exploratory analyses, pre-blina flow MRD+ status remained associated with inferior DFS (p = 0.0005) and OS (p < 0.0001) for patients who did not receive a subsequent hematopoietic cell transplant (HCT) in CR1, but not in patients who did (p = 0.55 and p = 0.99, respectively). In summary, flow MRD+ status before blina consolidation was associated with inferior survival in patients with Ph+ B-ALL in CR1 despite subsequent clearance, and consolidative HCT may reduce this prognostic effect.

15 August 2026 in Cancer
Verified
Journal Article
Closed access
IVIoannis Kalogirou Valtis
Ioannis Kalogirou Valtis
BFBenjamin F. Frost
Benjamin F. Frost
DNDavid Nemirovsky
David Nemirovsky
ADAndriy Derkach
Andriy Derkach
KCKuo‐Kai Chin
Kuo‐Kai Chin
ECEvan C. Chen
Evan C. Chen

15 October 2026 in Transplantation and Cellular Therapy
Verified
Journal Article
Closed access
NONatalia Tijaro Ovalle
Natalia Tijaro Ovalle
MBMaria Bromberg
Maria Bromberg
RTRoni Tamari
Roni Tamari
ALAndrew Lin
Andrew Lin
VTVishwamber Talla
Vishwamber Talla
MSMichael Scordo
Michael Scordo